Our next Patient Information Update will be from Edmonton, Alberta, on April 29th. All members were sent a Save the Date; if you didn’t receive the email, please check your spam/junk.
If you are unable to locate the email, simply email Daphne at office@haecanada.org with your updated email address to ensure future updates and registration details reach you.
thank you!
Latest News
TAKHZYRO now available in Newfoundland & Labrador
We love sharing amazing news, and now we have even more to love! On March
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even
A New CSL Behring Patient Support Program
We wanted to let our members know that starting February 1st, 2021, CSL Behring patient
Have no fear, the COVID vaccine is safe
Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
